FDA Warns Chantix May Up Heart Risk

A meta-analysis ordered by the agency and conducted by drugmaker Pfizer found a higher occurrence of major adverse cardiovascular events — including death, MI, and stroke — with the drug than with placebo.

The FDA noted, however, that such events were uncommon in both groups, and the increased risk wasn’t statistically significant.

via Chantix May Up Heart Risk, FDA Warns.

Quitting smoking is good.  Maybe quitting smoking without a pharmaceutical assist is better.  Additional link to the FDA release follows.

Safety Alerts for Human Medical Products > Chantix (Varenicline): Safety Communication – Updated Safety Review On The Risk of Cardiovascular Adverse Events.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s